If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) but aren't sure what puts someone at higher risk. Decades of pharmacovigilance have established that PML risk is linked to specific, measurable factors. This page explains the evidence behind those risk factors and what monitoring can look like.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling and adverse-event surveillance to describe the clinical presentation, pharmacological context, mechanistic pathways, and risk-management considerations relevant to patients and legal counsel. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early symptoms may be subtle and include progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual changes, or speech difficulties. Diagnosis relies on MRI imaging showing characteristic white-matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can mimic multiple sclerosis relapses, prompt evaluation is critical. The FDA label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune-cell migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus, creating a permissive environment for viral reactivation and PML development. The FDA Adverse Event Reporting System (FAERS) lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the spectrum of neurological symptoms that may overlap with PML presentation.
The link between Tysabri and PML is well established. The drug's inhibition of lymphocyte trafficking into the brain reduces JC virus-specific T-cell surveillance, allowing latent JC virus to replicate and cause lytic infection of oligodendrocytes. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors are multiplicative; patients who are anti-JCV antibody positive and have received Tysabri for more than two years face the highest risk. The label emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The prescribing information for Tysabri includes a boxed warning that explicitly states the drug increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients and prescribers are informed about PML risk and that monitoring occurs. Despite these measures, questions may arise regarding whether the warnings were sufficiently communicated to individual patients, particularly those who developed PML after prolonged therapy or after switching from prior immunosuppressants. The label's risk-factor discussion provides a framework for assessing whether a patient's specific risk profile was adequately addressed.
For patients who develop PML after Tysabri treatment, legal considerations often involve evaluating whether the manufacturer provided adequate warnings and whether the patient's treating physician appropriately monitored for PML symptoms. The timeline between exposure and documented harm is critical: PML typically occurs after months to years of Tysabri use, with risk increasing beyond two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who received Tysabri for shorter durations or who tested negative for anti-JCV antibodies may have a lower baseline risk, but PML can still occur. Settlement considerations may include medical expenses, loss of income, pain and suffering, and the need for lifelong care. Legal counsel should review the patient's treatment history, anti-JCV antibody status, and any documented discussions about PML risk.
The FDA label identifies longer treatment duration, especially beyond two years, as a known risk factor for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This temporal relationship is consistent with the gradual loss of JC virus-specific immune surveillance. Cases of PML have been reported as early as a few months after starting Tysabri, but the majority occur after 24 or more infusions. The label advises that physicians should consider the expected benefit of Tysabri relative to PML risk when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, the interval between the last Tysabri infusion and symptom onset can vary, and early diagnosis is crucial because prompt discontinuation of the drug and initiation of plasma exchange may improve outcomes.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA label includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three key risk factors are: presence of anti-JCV antibodies, treatment duration beyond two years, and prior use of immunosuppressants. These factors are multiplicative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Patients may pursue a settlement by evaluating whether the manufacturer provided adequate warnings and whether monitoring was appropriate. Legal counsel can review treatment history, antibody status, and documented risk discussions. Settlement may cover medical expenses, lost income, pain and suffering, and lifelong care.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.